Sigma Life Science has announced that it has added 2,200 Prestige Antibodies powered by Atlas Antibodies to its portfolio.
The development brings Sigma Life Science's total Prestige Antibody portfolio to 8,300, covering 6,900 human protein targets and expanding the company's overall monoclonal and polyclonal antibody offering to more than 30,000.
The company entered into its partnership with Atlas Antibodies in February 2008.
Under the terms of this partnership, both companies share co-exclusive distribution in Europe, while Sigma-Aldrich is the exclusive distributor in the North American, Asia Pacific and South American regions.
Prestige Antibodies are validated by the Human Protein Atlas (HPA) programme, a genome-wide programme with a primary goal of producing a complete localisation map of the human proteome, which currently contains expression profiles and sub-cellular localisation for close to 7,000 proteins.
The goal of the Human Protein Atlas is to develop at least one antibody to all 20,265 non-redundant human proteins by 2015.
Each antibody is standardised in universal protocols with more than 700 immunohistochemistry, immunofluorescence and Western blot images per antibody and all data is publicly available through the Human Protein Atlas.
